604 related articles for article (PubMed ID: 19856578)
1. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease: review and nursing implications.
Mattson MR
Clin J Oncol Nurs; 2007 Jun; 11(3):325-8. PubMed ID: 17623617
[TBL] [Abstract][Full Text] [Related]
5. An overview of chronic oral graft-vs-host disease following pediatric hematopoietic stem cell transplantation.
da Fonseca MA; Hong C
Pediatr Dent; 2008; 30(2):98-104. PubMed ID: 18481573
[TBL] [Abstract][Full Text] [Related]
6. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
Auletta JJ; Cooke KR
Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
[TBL] [Abstract][Full Text] [Related]
8. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
9. GVHD: overview on pathophysiology, incidence, clinical and biological features.
Klingebiel T; Schlegel PG
Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S45-9. PubMed ID: 9630325
[TBL] [Abstract][Full Text] [Related]
10. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of graft-versus-host disease.
Ferrara JL; Reddy P
Semin Hematol; 2006 Jan; 43(1):3-10. PubMed ID: 16412784
[TBL] [Abstract][Full Text] [Related]
12. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
13. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
[TBL] [Abstract][Full Text] [Related]
14. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
16. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
17. Life-threatening graft-vs-host disease.
Vargas-Díez E; García-Díez A; Marín A; Fernández-Herrera J
Clin Dermatol; 2005; 23(3):285-300. PubMed ID: 15896544
[TBL] [Abstract][Full Text] [Related]
18. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
20. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
